Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.20EUR
22 Feb 2019
Change (% chg)

€0.20 (+0.21%)
Prev Close
€96.00
Open
€95.96
Day's High
€96.50
Day's Low
€95.46
Volume
387,634
Avg. Vol
561,638
52-wk High
€100.20
52-wk Low
€74.54

Chart for

About

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and... (more)

Overall

Beta: 0.88
Market Cap(Mil.): €12,433.10
Shares Outstanding(Mil.): 129.24
Dividend: 1.25
Yield (%): 1.30

Financials

  MRCG.DE Industry Sector
P/E (TTM): 21.97 32.35 35.75
EPS (TTM): 4.38 -- --
ROI: 7.06 13.02 12.61
ROE: 13.49 14.07 13.81

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

FRANKFURT GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Feb 05 2019

Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 bln

FRANKFURT, Feb 5 GlaxoSmithKline bolstered its cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Feb 05 2019

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

Dec 21 2018

Palantir to offer cancer analytics under JV deal with Germany's Merck

((This NOV 19 story corrects to show Merck is Palantir's exclusive partner within the JV, not for all of Palantir's healthcare activities, paragraph 11))

Nov 20 2018

CORRECTED-UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up a cancer data analytics joint venture with German lab supplies company Merck KGaA, as the U.S. analytics and security firm makes further inroads into health care.

Nov 20 2018

Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up an exclusive cancer research joint venture with German lab supplies company Merck KGaA, as the U.S. data analytics and security firm makes further inroads into health care.

Nov 19 2018

Merck KGaA third-quarter earnings down on weak Latam currencies

FRANKFURT German drugs and lab supplies maker Merck KGaA saw adjusted core earnings decline and lowered its full-year profit outlook as a decline in Latin American currencies weighed on the value of overseas sales.

Nov 14 2018

Earnings vs. Estimates